Skip to main content

Table 2 Adverse events

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

  All
(N = 83) (%)
No ascites
(N = 43) (%)
Small to moderate ascites
(N = 26) (%)
Massive ascites
(N = 14) (%)
P valuea
All (%) Gr3-4 (%) All (%) Gr3-4 (%) All (%) Gr3-4 (%) All (%) Gr3-4 (%)
Hematological toxicity
 Any 70 (84) 52 (63) 35 (81) 22 (51) 24 (92) 20 (77) 11 (79) 10 (71) 0.076
 Neutropenia 61 (73) 40 (48) 30 (70) 19 (44) 21 (81) 19 (73) 10 (71) 8 (57) 0.064
 Leukopenia 59 (71) 32 (39) 29 (67) 11 (26) 20 (77) 14 (54) 10 (71) 7 (50) 0.041
 Anemia 27 (33) 8 (10) 15 (35) 4 (9) 9 (35) 3 (12) 3 (21) 1 (7) 0.49
 Thrombocytopenia 8 (10) 3 (4) 4 (9) 3 (7) 3 (12) 0 1 (7) 0 0.72
Nonhematological toxicity
 Any 76 (92) 10 (12) 39 (91) 4 (9) 24 (92) 4 (15) 13 (93) 2 (14) 0.72
 Fatigue 38 (46) 0 20 (47) 0 9 (35) 0 9 (64) 0 0.23b
 Neuropathy 38 (46) 0 23 (53) 0 11 (42) 0 6 (43) 0 0.87b
 Anorexia 37 (45) 6 (7) 17 (40) 2 (5) 12 (46) 3 (12) 8 (57) 1 (7) 0.56
 Hypertention 24 (29) 2 (2) 11 (26) 0 10 (38) 1 (4) 3 (21) 1 (7) 0.27
 Peripheral edema 23 (28) 0 11 (26) 0 7 (27) 0 5 (36) 0 0.74b
 Proteinuria 9 (11) 0 4 (9) 0 5 (19) 0 0 0 0.12b
 Diarrhea 8 (10) 0 6 (14) 0 1 (4) 0 1 (7) 0 0.36b
 Epistaxis 8 (10) 0 5 (12) 0 1 (4) 0 2 (14) 0 0.62b
 Febrile netropenia 3 (4) 3 (4) 3 (7) 3 (7) 0 0 0 0 0.26
  1. aComparison in grade 3 or 4
  2. bComparison in all grades